insulin aspart (Fiasp)
following an abbreviated submission:
insulin aspart (Fiasp®) is accepted for use within NHS Scotland.
Indication under review: treatment of diabetes mellitus in adults.
Insulin aspart (Fiasp®) is a new formulation with a faster onset of action than another formulation of insulin aspart and is available at an equivalent cost.
|Drug Name:||insulin aspart (Fiasp)|
|SMC Drug ID:||1227/17|
|Manufacturer:||Novo Nordisk Ltd|
|Indication:||Treatment of diabetes mellitus in adults.|
|Sub Category:||6.1 Drugs used in diabetes|
|Submission Type:||Abbreviated Submission|
|Date Advice Published:||10 April 2017|